It's still an expense though, so I disagree. NPAT is incredibly important IMHO and more important than EBIT.
Horses for courses, but NPAT is still the real bottom line for me.
So NPAT "linear" at best, but it was still negative IMO.
There is also competitor snapping at heels which is in FDA process. Disc Medicine, BEACON. Look it up.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$10.16 |
Change
-0.190(1.84%) |
Mkt cap ! $509.2M | |||
| Open | High | Low | Value | Volume |
| $10.35 | $10.44 | $10.15 | $621.4K | 60.52K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2039 | $10.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.17 | 124 | 1 |
View Market Depth
| Last trade - 16.13pm 04/07/2025 (20 minute delay) ? |
| CUV (ASX) Chart |